| Year |
Citation |
Score |
| 2018 |
Semenova G, Stepanova D, Karchugina S, Dubyk C, Deyev S, Lazar A, Chernoff J. Abstract B066: Unique roles of group I PAK isoforms in regulating MPNST cell viability Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B066 |
0.622 |
|
| 2017 |
Araiza-Olivera D, Feng Y, Semenova G, Prudnikova TY, Rhodes J, Chernoff J. Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors. Oncogene. PMID 29059171 DOI: 10.1038/Onc.2017.400 |
0.68 |
|
| 2017 |
Stepanova DS, Semenova G, Kuo YM, Andrews AJ, Ammoun S, Hanemann CO, Chernoff J. An essential role for the tumor suppressor Merlin in regulating fatty acid synthesis. Cancer Research. PMID 28729415 DOI: 10.1158/0008-5472.Can-16-2834 |
0.723 |
|
| 2017 |
Semenova G, Stepanova DS, Dubyk C, Handorf E, Deyev SM, Lazar AJ, Chernoff J. Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis. Oncogene. PMID 28534510 DOI: 10.1038/Onc.2017.143 |
0.756 |
|
| 2017 |
Semenova G, Chernoff J. Targeting PAK1. Biochemical Society Transactions. 45: 79-88. PMID 28202661 DOI: 10.1042/BST20160134 |
0.602 |
|
| 2017 |
Semenova G, Stepanova D, Deyev SM, Chernoff J. Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type I. Biochimie. PMID 28065690 DOI: 10.1016/J.Biochi.2017.01.001 |
0.719 |
|
| 2015 |
Semenova G, Chernoff J. Abstract 1026: Role of Group I Paks in MPNST cell proliferation, migration and invasion Cancer Research. 75: 1026-1026. DOI: 10.1158/1538-7445.Am2015-1026 |
0.734 |
|
| 2014 |
Radu M, Semenova G, Kosoff R, Chernoff J. PAK signalling during the development and progression of cancer. Nature Reviews. Cancer. 14: 13-25. PMID 24505617 DOI: 10.1038/Nrc3645 |
0.73 |
|
| 2012 |
Semenova G, Chernoff J. PKM2 enters the morpheein academy. Molecular Cell. 45: 583-4. PMID 22405271 DOI: 10.1016/J.Molcel.2012.02.014 |
0.569 |
|
| Show low-probability matches. |